ストックスクリーナーアプリを入手
31.35
0.06%
-0.02
プレマーケット:
31.26
-0.09
-0.29%
Catalyst Pharmaceuticals Inc (CPRX) 最新ニュース
The Technical Signals Behind (CPRX) That Institutions Follow - Stock Traders Daily
Angelini Pharma to buy Catalyst in deal worth $4.1 billion - MSN
HC Wainwright & Co. Downgrades Catalyst Pharmaceuticals (CPRX) - MSN
Catalyst Investor Sues Over Proposed $4.1B Angelini Buyout - Law360
Catalyst (CPRX) up 0.6% since last earnings report: Can it continue? - MSN
Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Angelini Pharma to buy Catalyst (CPRX) for $31.50 per share; virtual vote July 8 - Stock Titan
Catalyst Pharmaceuticals (CPRX) CMO gets 3,052 shares, 743 withheld for tax - Stock Titan
Dakota Review Highlights Broad-Based Strength in May 2026 Private Markets Activity - TipRanks
Homogeneous Catalyst Market Growth Outlook to 2035: Trends, Drivers, and Regional AnalysisNews and Statistics - IndexBox
Precision Trading with Catalyst Pharmaceuticals Inc. (CPRX) Risk Zones - Stock Traders Daily
CPRX PE Ratio & Valuation, Is CPRX Overvalued - Intellectia AI
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer - news.financial
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
D.R. Horton Inc. (DHI) Q1 2026 Earnings: Slight EPS Beat Amid Mixed Housing ConditionsEarnings Growth Analysis - thelegaladvocate.com
H.C. Wainwright Maintains Catalyst Pharmaceuticals(CPRX.US) With Hold Rating, Maintains Target Price $31.5 - Moomoo
Catalyst (CPRX) to be acquired by Angelini Pharma for $31.50 per share (cash) - Stock Titan
H.C. Wainwright Downgrades Catalyst Pharmaceuticals(CPRX.US) to Hold Rating, Cuts Target Price to $31.5 - Moomoo
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term - Yahoo Finance
CPRX Technical Analysis | Trend, Signals & Chart Patterns | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance
Technical Reactions to CPRX Trends in Macro Strategies - Stock Traders Daily
Angelini Buyout And FIRDAPSE Settlement Reframe Catalyst Pharmaceuticals Story - Yahoo Finance
Third Avenue Management's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Catalyst Pharmaceuticals Q1 earnings beat, Firdapse revenues rise Y/Y - MSN
Angelini Buyout And Firdapse Settlement Reframe Catalyst Pharmaceuticals Story - Sahm
Catalyst Pharmaceuticals, Inc.Common Stock (NQ: CPRX - FinancialContent
Angelini Interest Puts Catalyst Pharmaceuticals Rare Disease Value In Focus - Sahm
Catalyst Pharmaceuticals: Angelini Deal Caps A Potentially Better Story (NASDAQ:CPRX) - Seeking Alpha
CPRX SWOT Analysis: Strong Financials Amidst Market Challenges R - GuruFocus
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y - Yahoo Finance
Trading the Move, Not the Narrative: (CPRX) Edition - Stock Traders Daily
Catalyst Pharmaceuticals earnings beat by $0.06, revenue topped estimates - Investing.com Canada
Catalyst Pharmaceuticals (CPRX) Announces Suspension of Guidance Updates - GuruFocus
Catalyst Pharmaceuticals, Inc. Q1 2026 earnings preview - MSN
CPRX Reports Impressive Q1 Revenue Growth - GuruFocus
Catalyst Pharma Reports Higher Revenue, Suspends Earnings Guidance - TipRanks
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Catalyst Pharmaceuticals 1Q EPS 50c >CPRX - Moomoo
Profit rises at Catalyst Pharmaceuticals (NASDAQ: CPRX) on Q1 2026 results - Stock Titan
Catalyst Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise - marketscreener.com
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results - The Manila Times
Earnings Flash (CPRX) Catalyst Pharmaceuticals, Inc. Reports Q1 Revenue $149.4M, vs. FactSet Est of $149.5M - marketscreener.com
Earnings Flash (CPRX) Catalyst Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.79 per Share, vs. FactSet Est of $0.65 - marketscreener.com
Earnings Flash (CPRX) Catalyst Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.79 per Share, Vs. FactSet Est of $0.65 - Moomoo
BRIEF-Catalyst Pharmaceuticals Q1 Revenue USD 149.4 Million Vs. IBES Estimate USD 148.2 Million - TradingView
Catalyst Pharma (NASDAQ: CPRX) posts Q1 profit ahead of Angelini deal - Stock Titan
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):